News Release For Immediate Release

 

Investor Contact:
Julie Pekarek
Chief Marketing Officer
414.977.4254
ir@merge.com

 

MERGE HEALTHCARE REPORTS CONTINUED REVENUE GROWTH

Milwaukee, WI, October 29, 2009 – Merge Healthcare Incorporated (NASDAQ: MRGE), a health IT
solutions provider, today announced financial results for the third quarter of 2009.

“Our focus on the integration of our two acquisitions in the third quarter has driven a financial
performance that exceeded our expectations.” said Justin Dearborn CEO. “We are excited about the
improvement we continue to see in sales pipeline activity and customer bookings since these acquisitions closed. We expect that a continuation of this should lead to GAAP net income for the acquired entities beginning in the fourth quarter of 2009.”

“We have managed the business through a down cycle in the economy and depressed spending in our customer base. We are encouraged at the improvement starting to be felt in both.”

Mr. Dearborn further noted that the acquisitions of etrials Worldwide, Inc. (“etrials”, formerly NASDAQ:
ETWC) and Confirma, Inc. (“Confirma”):

Increase Merge’s addressable market;

Create organic growth opportunities through improved cross-selling activity; and

Are expected to be accretive in 2010.

Quarter Results:
Results compared to the same quarter in the prior year, as well as the prior quarter are as follows (in
millions):

	Q3 2009	Q3 2008	Q2 2009
Net Sales	$16.9	$14.6	$15.4
Operating Income (loss)	(0.2)	1.3	4.1
Net income (loss)	(0.9)	0.4	0.4
EBITDA	1.9	3.1	2.8
Adjusted EBITDA*	4.8	2.9	6.3
Earnings (loss) per diluted share	$(0.02)	$0.01	$0.01
Adjusted EBITDA per share	$0.08	$0.05	$0.11

 

The third quarter of 2009 includes the results of etrials since July 20, 2009, and the results of Confirma
since September 1, 2009, which are the respective dates we completed these two acquisitions. These
results do not include $0.6 million in revenue that could not be recognized under GAAP due to the
purchase accounting treatment related to the acquired entities. The impact on revenue due to purchase accounting treatment is anticipated to be $1.0 million in the fourth quarter of 2009 and $1.3 million for the full year 2010.

In the third quarter of 2009, the cash balance decreased by $3.1 million to $16.9 million at September 30, 2009. Cash generated from operating activities was $1.1 million, which was offset by $5.1 million of net cash paid for the two strategic acquisitions.

Year-to-Date Results:
Merge’s financial results for the nine months ended September 30, 2009, compared to the nine months ended September 30, 2008 are as follows (in millions):

	2009	2008
Net sales	$47.6	$41.7
Operating income (loss)	7.5	(25.4)
Net income (loss)	2.4	(25.6)
EBITDA*	10.0	(17.9)
Adjusted EBITDA*	16.3	(6.1)
Earnings (loss) per diluted share	$0.04	$(0.59)
Adjusted EBITDA per share*	$0.27	$(0.14)

 

View Full Financial Tables >>

 

Conference Call Information:
Merge will hold a public web cast today at 9:00 AM EDT to review these financial results and to provide
an update on business operations and strategy. Immediately following, there will be a question and
answer session.

Investors will have the opportunity to listen to the conference call via telephone or over the Internet at
Merge Healthcare Web Cast. To access the call, dial 1.800.221.2015 or 706.634.2159. The Conference ID Number to reference is 35849235. A replay via the Internet or telephone will be available shortly after the call at http://www.merge.com/investor/conferencecall.asp.

---

 

Merge Healthcare Incorporated develops solutions that automate healthcare data and diagnostic workflow to enable a better electronic record of the patient experience, and to enhance product development for health IT, device and pharmaceutical companies. Merge products, ranging from standards-based development toolkits to sophisticated clinical applications, have been used by healthcare providers, vendors and researchers worldwide for over 20 years. Additional information can be found at www.merge.com.

* Non-GAAP Measures
The non-GAAP measures EBITDA and adjusted EBITDA shown in this release exclude impairment of
investments, sale of non-core patents, acquisition related costs, acquisition related severance (not
qualifying for restructuring cost) and restructuring, tradename impairment and other costs and expenses. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included after the financial information included in this press release. These measures are not in accordance with, or an alternative for, GAAP and may be different from non-GAAP measures used by other companies. Management believes that the presentation of non-GAAP results, when shown in conjunction with corresponding GAAP measures, provides useful information to management and investors regarding financial and business trends related to our results of operations. Further, management believes that these non-GAAP measures improve management’s and investors’ ability to compare Merge’s financial performance with other companies in the technology industry. Because certain charges, costs and expenses reflect events that are not essential to our recurring business operations, it is useful to compare results excluding these amounts. Management also uses financial statements that exclude these charges costs and expenses for its internal budgets and EBITDA is a measure used in a debt covenant in our credit facility. While GAAP results are more complete, we offer investors these supplemental metrics since, with reconciliations to GAAP, they may provide greater insight into our financial results. Management does not intend the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non- GAAP financial measures should be read only in conjunction with the consolidated financial statements prepared in accordance with GAAP.

 

Forward Looking Statements

Information included in this news release may contain forward-looking statements, concerning, among
other things, Merge’s outlook, financial projections and business strategies, all of which are subject to
risks, uncertainties and assumptions. These forward-looking statements are identified by their use of
terms such as “intend,” “plan,” “may,” “should,” “will,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “continue,” “potential,” “opportunity,” “project” and similar terms. These statements are based on certain
assumptions and analyses that Merge believes are appropriate under the circumstances. Should one or
more of these risks or uncertainties materialize, or should the assumptions prove incorrect, actual results
may differ materially from those expected, estimated or projected. Merge can not guarantee that it will
achieve these plans, intentions or expectations. Forward-looking statements speak only as of the date
they are made, and Merge undertakes no obligation to publicly update or revise any of them in light of
new information, future events or otherwise, except as required by law. Factors that could have a
material adverse effect on operations and future prospects of Merge include, but are not limited to: market
acceptance and performance of Merge’s products and services; the impact of competitive products and
pricing; the risks and effects of its recent securities issues; the past restatement of our financial
statements; the amount of the costs, fees, expenses and charges related to the acquisition of etrials
Worldwide, Inc. (“etrials”), Confirma, Inc. (“Confirma”) and other non-material acquisitions; the ability of
Merge Healthcare to integrate its acquisitions, such as etrials and Confirma, successfully; whether the
acquisitions will result in the enhancement of value and benefits to customers and to Merge Healthcare’s,
etrials’ and Confirma’s stockholders; general economic and business conditions; global economic growth
and activity; industry conditions; and changes in laws or regulations, including but not limited to U.S.
health care reform; our ability to generate sufficient cash from operations to meet future operating,
financing and capital requirements, including repayment obligations with respect to our outstanding
indebtedness; risks associated with our prior delays in filings with the SEC or our ability to continue to
meet the listing requirements of The NASDAQ Stock Market; the costs, risks and effects of various
pending legal proceedings and investigations, including the formal investigation being conducted by the
Securities and Exchange Commission; and other risk factors detailed in our filings with the Securities and
Exchange Commission. These uncertainties and risks may cause our actual future results to be
materially different than those expressed in our forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the date the
statement was made. We undertake no obligation to update such forward-looking statements or any of
such risks, uncertainties and other factors, except as required by law.